Analgesizing effect of a methyl donor (S-adenosylmethionine) in migraine: an open clinical trial.
The long term administration of a methyl donor (S-adenosylmethionine, SAM) relieves pain in migraine sufferers. The benefit arises gradually and long-term treatment is required for therapeutic effectiveness. Since SAM is an almost ubiquitous methyl donor in many biological systems, an explanation of this peculiar therapeutic effect is only speculative. The activity of SAM on 5-hydroxytryptamine turnover is the most reasonable interpretation of the results.